Zila, Inc. (ZILAD) Retains William Blair & Company to Review Strategic Alternatives
Zila, Inc. (NASDAQ: ZILAD) has retained investment bank William Blair & Company to assist it in exploring strategic business opportunities.
"In recent months, we have established a solid foundation upon which to grow our business by reducing expenses, restructuring our operations and adding new international markets for ViziLite(R) Plus," said David Bethune, chairman and chief executive officer of Zila. "The engagement of William Blair is an important element in our plan to shore up our capital structure and further evaluate opportunities for growth."
Zila, Inc. (Zila) is a specialty pharmaceutical company engaged towards prevention, detection and treatment of oral diseases with a focus on oral cancer. [SM]
"In recent months, we have established a solid foundation upon which to grow our business by reducing expenses, restructuring our operations and adding new international markets for ViziLite(R) Plus," said David Bethune, chairman and chief executive officer of Zila. "The engagement of William Blair is an important element in our plan to shore up our capital structure and further evaluate opportunities for growth."
Zila, Inc. (Zila) is a specialty pharmaceutical company engaged towards prevention, detection and treatment of oral diseases with a focus on oral cancer. [SM]
You May Also Be Interested In
- UPDATE: William Blair Starts EPIQ Systems (EPIQ) at Outperform; Broad Suite of Solutions in Electronic Discovery Sector
- Dow Chemical (DOW) Wins $2.16B in K-Dow Arbitration
- DISH Network (DISH) Sued by Networks for 'Commercial Skipping' Feature
Create E-mail Alert Related Categories
Corporate NewsRelated Entities
William BlairSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
